PL2187880T3 - Kompozycje i sposoby do leczenia zwyrodnienia plamki żółtej - Google Patents

Kompozycje i sposoby do leczenia zwyrodnienia plamki żółtej

Info

Publication number
PL2187880T3
PL2187880T3 PL08830106T PL08830106T PL2187880T3 PL 2187880 T3 PL2187880 T3 PL 2187880T3 PL 08830106 T PL08830106 T PL 08830106T PL 08830106 T PL08830106 T PL 08830106T PL 2187880 T3 PL2187880 T3 PL 2187880T3
Authority
PL
Poland
Prior art keywords
compositions
methods
macular degeneration
treating macular
treating
Prior art date
Application number
PL08830106T
Other languages
English (en)
Inventor
Ilyas Washington
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40452355&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2187880(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Columbia filed Critical Univ Columbia
Publication of PL2187880T3 publication Critical patent/PL2187880T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
PL08830106T 2007-09-12 2008-09-12 Kompozycje i sposoby do leczenia zwyrodnienia plamki żółtej PL2187880T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99337907P 2007-09-12 2007-09-12
PCT/US2008/010676 WO2009035673A1 (en) 2007-09-12 2008-09-12 Compositions and methods for treating macular degeneration
EP08830106.4A EP2187880B1 (en) 2007-09-12 2008-09-12 Compositions and methods for treating macular degeneration

Publications (1)

Publication Number Publication Date
PL2187880T3 true PL2187880T3 (pl) 2014-05-30

Family

ID=40452355

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08830106T PL2187880T3 (pl) 2007-09-12 2008-09-12 Kompozycje i sposoby do leczenia zwyrodnienia plamki żółtej

Country Status (8)

Country Link
US (4) USRE47045E1 (pl)
EP (2) EP2187880B1 (pl)
JP (2) JP5149388B2 (pl)
DK (1) DK2187880T3 (pl)
ES (1) ES2449150T3 (pl)
PL (1) PL2187880T3 (pl)
PT (1) PT2187880E (pl)
WO (1) WO2009035673A1 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3326623A1 (en) 2003-03-14 2018-05-30 University of Washington Retinoid replacements and opsin agonists and methods for the use thereof
NZ587006A (en) 2004-06-18 2011-12-22 Univ Washington 11-cis-Retinal derivatives and methods for the use thereof for the treatment of visual disorders
WO2009035673A1 (en) 2007-09-12 2009-03-19 Trustees Of Columbia University In The City Of Newyork Compositions and methods for treating macular degeneration
WO2009102418A1 (en) 2008-02-11 2009-08-20 University Of Washington Methods for the treatment and prevention of age-related retinal dysfunction
US20090312438A1 (en) * 2008-06-13 2009-12-17 Bernstein Paul S Compositions and Methods for Attenuating the Formation of A2E in the Retinal Pigment Epithelium
CN102612375B (zh) 2009-09-15 2016-01-27 Qlt股份有限公司 含有在脂质媒介物中的9-顺式-视黄酯的药物制剂
CN107308143A (zh) 2010-04-19 2017-11-03 诺维利昂治疗股份有限公司 用于治疗或改善与内源性类视黄醇缺乏有关的视觉障碍的治疗方案和方法
JP6576636B2 (ja) 2012-03-01 2019-09-18 ノベリオン セラピューティクス インコーポレイテッド 内因性レチノイド欠乏に関連する視覚障害における視覚機能を改善するための治療的計画および方法
WO2013185055A1 (en) 2012-06-07 2013-12-12 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of pin1
ES3012058T3 (en) * 2014-02-13 2025-04-08 Katairo Gmbh Compounds for the treatment of lipofuscin related diseases
US20170112792A1 (en) * 2014-03-21 2017-04-27 Beth Israel Deaconess Medical Center, Inc. Enhanced atra-related compounds derived from structure-activity relationships and modeling for inhibiting pin1
WO2016011265A2 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Biomarkers for pin1-associated disorders
KR102276424B1 (ko) * 2014-10-06 2021-07-12 삼성전자주식회사 로-키나제 저해제를 포함하는 세포의 노화를 감소시키기 위한 조성물 및 그의 용도
US9173915B1 (en) 2014-10-10 2015-11-03 Peter F. Kador Antioxidant eye drops
US10548864B2 (en) 2015-03-12 2020-02-04 Beth Israel Deaconess Medical Center, Inc. Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
US20200025685A1 (en) * 2016-12-15 2020-01-23 Codiak Biosciences, Inc. Methods of measuring exosomes using intrinsic fluorescence
CN118121573B (zh) * 2022-12-01 2025-08-05 复旦大学 一种氘代维生素a及其衍生物的用途
EP4731619A2 (en) * 2023-06-20 2026-04-29 The Trustees Of Columbia University In The City Of New York Novel co-drug, co-administration, and sequential administration of bispecific rbp4/ttr ligand and c20-d3-retinol
AU2024312789A1 (en) * 2023-06-20 2026-01-29 Rensselaer Polytechnic Institute Novel co-drug, co-administration, and sequential administration of selective ttr ligand and c20-d3-retinol
WO2025147228A1 (en) 2024-01-02 2025-07-10 Alkeus Pharmaceuticals, Inc. Treatment for asymptomatic stargardt disease patients with gildeuretinol acetate
WO2025147467A1 (en) 2024-01-02 2025-07-10 Alkeus Pharmaceuticals, Inc. 10mg to 35mg of gildeuretinol for use in the treatment of stargardt disease
WO2025153898A1 (en) * 2024-01-19 2025-07-24 Gene Company Pty Ltd Retinoid compositions and methods of use
WO2026050657A1 (en) 2024-08-30 2026-03-05 Alkeus Pharmaceuticals, Inc. Gildeuretinol for use for treating geographic atrophy and neovascular age-related macular degeneration
CN120441428A (zh) * 2025-05-15 2025-08-08 复旦大学 一种双异戊二烯衍生物及其用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310764A (en) 1992-05-08 1994-05-10 Steven Baranowitz Treatment of age related macular degeneration with beta-carotene
US5508456A (en) * 1993-07-30 1996-04-16 Ligand Pharmaceuticals Incorporated 9-cis tritium-labeled retinoids and intermediates, methods for their synthesis and methods for their use in discovering retinoid X receptor ligands
US5489611A (en) 1995-02-10 1996-02-06 Warner-Lambert Company Method for lowering plasma levels of lipoprotein (a)
US8198334B2 (en) 1997-10-27 2012-06-12 Pathologica Llc Methods for modulating macrophage proliferation in ocular disease using polyamine analogs
US6593104B1 (en) 1999-02-12 2003-07-15 University Of Iowa Research Foundation Macular degeneration diagnostics and therapeutics
US20030149997A1 (en) 1999-02-19 2003-08-07 Hageman Gregory S. Diagnostics and therapeutics for arterial wall disruptive disorders
CA2385475A1 (en) 1999-08-16 2001-02-22 Human Genome Sciences, Inc. 18 human secreted proteins
US20040009907A1 (en) 2001-02-26 2004-01-15 Alsobrook John P. Proteins and nucleic acids encoding same
US20030032078A1 (en) 2001-01-23 2003-02-13 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of macular and retinal degenerations
NZ516873A (en) 2001-02-12 2003-11-28 Warner Lambert Co Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage
EP1368296A1 (en) 2001-03-14 2003-12-10 Eli Lilly And Company Fluorinated trienes and their use as rxr modulators
US6660297B2 (en) 2001-03-23 2003-12-09 Bausch & Lomb Incorporated Nutritional supplement to treat macular degeneration
US20040121407A1 (en) 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
JP2006516027A (ja) 2002-12-02 2006-06-15 ジェンベク、インコーポレイティッド 眼関連障害の治療用材料および治療方法
JP2006526662A (ja) 2003-06-05 2006-11-24 アシュカル，チャールズ 過増殖性細胞疾患を治療する方法
US7267830B2 (en) 2003-12-19 2007-09-11 Alcon, Inc. Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision
FR2864871A1 (fr) 2004-01-06 2005-07-08 Thomson Licensing Sa Methode de decouverte d'un reseau domestique et appareil implementant la methode
US7309487B2 (en) 2004-02-09 2007-12-18 George Inana Methods and compositions for detecting and treating retinal diseases
US7566808B2 (en) 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
CA2601278C (en) * 2004-03-17 2014-06-10 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
US20060089411A1 (en) * 2004-08-07 2006-04-27 Gierhart Dennis L Treatment of Stargardt's disease and other lipofuscin disorders with combined retinaldehyde inhibitor and zeaxanthin
AU2005287343A1 (en) * 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
EP1804788A4 (en) 2004-10-25 2008-05-21 Sirion Therapeutics Inc DETECTION AND ANALYSIS OF FLUORESCENT MOLECULES RELATING TO OPHTHALMOLOGY
JP2008519054A (ja) 2004-11-04 2008-06-05 シリオン セラピューティクス， インコーポレイテッド レチノール−レチノール結合タンパク質（ｒｂｐ）−トランスチレチン（ｔｔｒ）複合体の形成のモジュレーター
CA2584845C (en) 2004-12-08 2009-02-17 Sirion Therapeutics, Inc. Methods, assays and compositions for treating retinol-related diseases
US20070014833A1 (en) 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
US20060292099A1 (en) 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
AU2006249866B2 (en) 2005-05-26 2011-10-13 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
UA81382C2 (en) * 2005-07-11 2007-12-25 Composition for treating retinol-related diseases by modulation of retinol binding
JPWO2007037188A1 (ja) * 2005-09-27 2009-04-09 北海道公立大学法人 札幌医科大学 血管透過性亢進に起因する眼疾患の予防及び治療のための医薬
WO2009035673A1 (en) 2007-09-12 2009-03-19 Trustees Of Columbia University In The City Of Newyork Compositions and methods for treating macular degeneration
US8677809B2 (en) 2008-06-16 2014-03-25 Oxford Instruments Plc Thermal measurements using multiple frequency atomic force microscopy
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
ES2469849T3 (es) 2009-06-18 2014-06-20 Concert Pharmaceuticals Inc. Derivados deuterados de isoindolin-1,3-diona como inhibidores de PDE4 y TNF-alfa

Also Published As

Publication number Publication date
WO2009035673A8 (en) 2009-07-02
PT2187880E (pt) 2014-03-25
US20110034554A1 (en) 2011-02-10
US8877809B2 (en) 2014-11-04
US20150133549A1 (en) 2015-05-14
EP2187880A4 (en) 2010-09-08
US9486432B2 (en) 2016-11-08
ES2449150T3 (es) 2014-03-18
USRE47045E1 (en) 2018-09-18
JP5695017B2 (ja) 2015-04-01
JP2013049711A (ja) 2013-03-14
WO2009035673A1 (en) 2009-03-19
JP2010539168A (ja) 2010-12-16
EP2187880A1 (en) 2010-05-26
JP5149388B2 (ja) 2013-02-20
US20170128403A1 (en) 2017-05-11
EP2687208A1 (en) 2014-01-22
DK2187880T3 (da) 2014-03-10
EP2187880B1 (en) 2013-12-18

Similar Documents

Publication Publication Date Title
PT2187880E (pt) Composições e métodos para o tratamento da degenerescência macular
HRP20190214T1 (hr) Pripravci i metode za liječenje purpure
EP2170309A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES
SMT202300433T1 (it) Peptide per l'uso nella prevenzione o nel trattamento della degenerazione maculare
SI3190128T1 (sl) Sestavki in postopki za zdravljenje motenj, posredovanih z IgE
IL202573A0 (en) Methods and compositions for treating allergic diseases
IL202015A0 (en) Methods and compositions for treating skin conditions
IL215932A0 (en) Compositions and methods for treating burns
IL193014A0 (en) Methods and compositions for treating schizophrenia
EP2120561A4 (en) COMPOSITIONS FOR TREATING BIOFILMS, AND METHODS FOR THEIR USE
SI2374472T1 (sl) Sestavki in postopki za zdravljenje oftalmoloških motenj
ZA201101055B (en) Compositions and methods for treating osteoarthritis
GB2466912B (en) Compositions and methods for treating lysosomal disorders
IL251169A0 (en) Methods and preparations for stimulating the generation of nerve cells and inhibiting the degeneration of nerve cells through the use of isothiazolopyrimidinones
IL210097A0 (en) Compositions and methods for treating unfluenza
ZA200900140B (en) Methods and compositions for treating biofilms
PL2252317T3 (pl) Leczenie zwyrodnienia plamki żółtej
HUP0700369D0 (en) Pharmaceutical compositions and method for treating schizofrenia
HRP20130642T1 (en) Methods and compositions for treating cancers
WO2011097577A9 (en) Compositions and methods for treating or preventing retinal degeneration
IL173971A0 (en) Compositions and methods for treating and preventing age-related macular degeneration
ZA201108151B (en) Method and composition for treating macular degeneration
IL213550A0 (en) Method for treating macular degeneration
IL209947A0 (en) Compositions and methods for treating corneal inflammation
GB0625844D0 (en) The treatment of macular degeneration